| Program | Indication | Discovery | Preclinical | PhaseⅠ | PhaseⅡ | PhaseⅢ |
| Antibody Therapy | ||||||
| Antibody Product Portfolio | Cancer |
|
||||
| Anti-Scg3 Therapeutic Antibody | Diabetic Retinopathy |
|
||||
| ANTIGN-109 | Cancer |
|
||||
| ANTICA-201 | Cancer |
|
||||
| CD3XCD20 bsAb | Lymphomas |
|
||||
| Cl3hmAb | Acquired immune deficiency syndrome |
|
||||
| Anti-MUC1-Ab | Solid tumor |
|
||||
| CD3xBCMA-bsAb | Multiple myeloma |
|
||||
| LAG3-Ab | Cancer |
|
||||
| OX40-Ab | Cancer |
|
||||
| Recombinant Protein Therapy | ||||||
| P75NEURO | Neurological diseases |
|
||||
| P11 | Type 2 diabetes |
|
||||
| Angiocidin | Acute Myeloid Leukemia |
|
||||
| TT-173 | Surgical bleeding and trauma |
|
||||
| Oncolytic Virotherapy | ||||||
| RV-scFv-PDL1 | Cancer |
|
||||
| OV-FV-01 | Cancer |
|
||||
| Chemotherapy | ||||||
| Polyoxygenated cyclohexene compound 4 | Pain |
|
||||
| Fascin inhibitor | Cancer |
|
||||
| Mitochondrial uncoupling agent | Nonalcoholic steatohepatitis |
|
||||
| HBV capsid inhibitor | Hepatitis B |
|
||||
| KCNQ2/3 potassium channel opener | Epilepsy |
|
||||
| Resveratrol (micellar) | Alzheimer’s disease |
|
||||
| Inflammatory factor regulators | Psoriasis |
|
||||
| NMMHC IIA inhibitors | Thrombosis |
|
||||
| Cell Therapy | ||||||
| Double negative T cells | Acute myelocytic leukemia |
|
||||
| BCMA - CAR-T | Multiple myeloma |
|
||||
| RNA Therapy | ||||||
| RNA4TNBC | Triple-negative breast cancer |
|
||||
Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since.
 |
Protheragen Inc.
2200 Smithtown Avenue, Room 1, Ronkonkoma, |
 |
Quick Links |